文献速递膀胱癌与上尿路尿路上皮癌

非转移性肌层浸润性膀胱癌:年龄在决定是否接受根治性治疗中的作用

Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent.
PubMed 文献 · BJU Int · 2022-02-08

该队列研究纳入2005至2019年荷兰癌症登记处15047例cT2-T4aN0/xM0/x尿路上皮肌层浸润性膀胱癌患者,分析未接受治疗的相关因素并比较未治疗与治疗患者的生存。结果示≥75岁患者约三分之一未治疗,<75岁约十分之一未治疗;无论年龄,未治疗者中位总生存均显著更差。作者认为年龄本身不应影响治疗决策。

要点

  • ≥75岁患者约三分之一未接受根治性治疗,<75岁约十分之一未治疗。
  • 高龄、体能状态差、肾功能差、cT4a期及既往腹盆腔放疗增加未治疗 odds。
  • 无论年龄,未治疗者中位总生存显著差于治疗者。

核心结论

  • 平均五分之一非转移性肌层浸润性膀胱癌患者未接受治疗,未治疗者年龄更大且预后特征更不利。
  • 无论年龄,未治疗患者总生存均显著更差,年龄本身不应影响治疗决策。
  • 考虑到医院间差异大,部分未治疗患者可能被错误地拒绝延长生命的治疗。

研究设计与样本

  • 队列研究,纳入2005至2019年荷兰癌症登记处15047例cT2-T4aN0/xM0/x尿路上皮肌层浸润性膀胱癌患者。
  • 采用逻辑回归分析未治疗相关因素,多水平分析评估医院间差异,倾向评分评估中位总生存,分析按年龄<75岁与≥75岁分层。

主要发现

  • ≥75岁患者中三分之一未治疗;年龄增加、体能状态更差、肾功能更差、cT4a期及既往腹盆腔放疗增加未治疗 odds。
  • <75岁患者中十分之一未治疗;仅体能状态、肾功能和cT4a期有显著关联。
  • ≥75岁患者未治疗的医院间差异最大,病例组合调整后范围为37%至69%。
  • 无论年龄,未治疗患者中位总生存显著更差:6.4个月(95%CI 5.1-7.3)vs 治疗患者16.0个月(95%CI 13.5-19.1)。

临床怎么用

  • 作者认为年龄本身不应影响治疗决策。
  • 作者指出考虑到医院间差异大,部分未治疗患者可能被错误地拒绝延长生命的治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non-metastatic muscle-invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. PATIENTS AND METHODS: For this cohort study, 15 047 patients diagnosed with cT2-T4aN0/xM0/x urothelial MIBC between 2005 and 2019 were identified in the Netherlands Cancer Registry. Factors associated with remaining untreated were identified using logistic regression analyses. Interhospital variation was assessed using multilevel analysis. Using a propensity score, the median overall survival (mOS) of untreated and treated patients was evaluated. Analyses were stratified by age (<75 vs ≥75 years). RESULTS: One-third of patients aged ≥75 years remained untreated; increasing age, worse performance status, worse renal function, cT4a stage and previous radiotherapy in the abdomen/pelvic area increased the odds of remaining untreated. One in 10 patients aged <75 years remained untreated; significant associations were only found for performance status, renal function and cT4a stage. Interhospital variation for remaining untreated was largest for patients aged ≥75 years, ranging from 37% to 69% (case-mix-adjusted). Irrespective of age, mOS was significantly worse for untreated patients: 6.4 months (95% confidence interval [CI] 5.1-7.3) vs 16.0 months (95% CI 13.5-19.1) for treated patients. CONCLUSION: On average, one in five patients with non-metastatic MIBC remained untreated. Untreated patients were generally older and had a more unfavourable prognostic profile. Untreated patients had significantly worse overall survival, regardless of age. Age alone should therefore not affect treatment decision-making. Considering the large interhospital variation, a proportion of untreated patients might be wrongfully denied life-prolonging treatment.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. van Hoogstraten LMC, Witjes JA, Meijer RP, et al. Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent. BJU Int. 2022. PMID: 35064953. doi:10.1111/bju.15697

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。